BSE filing, BSE: 544353. Summary written from the filing by ALFA Finder's alert engine.
Amwill Health Care Ltd: key numbers
- Share price
- ₹43.00
- Market cap
- ₹86.02 Cr
- Revenue (annual)
- ₹45.49 Cr
- Net profit (annual)
- ₹11.42 Cr
- P/E (TTM)
- 7.5×Sector 46.5×
- Promoter holding
- 70.65%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amwill Health Care Ltd
All →Amwill Health Care Dividend
Amwill Health Care's board declared an interim dividend of Rs.0.05 per equity share for FY 2026-27 on 23 October 2026. The record date is 30 October 2026 and payment is proposed by 22 November 2026.
Amwill Health Care H1 FY27 Results: Net Profit ₹3.7 Cr, Down 50.7% YoY
Amwill Health Care Ltd reported revenue from operations of ₹22.6 Cr (-7.0% YoY) and net profit of ₹3.7 Cr (-50.7% YoY) for H1 FY27.
- Key figure
- Net profit ₹3.7 Cr · -50.7% YoY
Amwill Health Care Board Meeting Date
Amwill Health Care has scheduled a board meeting for October 23, 2026, to review H1 financial results and consider declaring an interim dividend.
Amwill Health Care Regulatory Approval
Amwill Health Care received an import license from CDSCO for FoliColor hair products, enabling the company to commence commercial sale and import into India.
Amwill Health Care Acquisition Worth ₹3 Cr
Amwill Health Care Limited approved investments of ₹3 Crore into two Alternative Investment Funds. The company will invest ₹1.50 Crore each in Vivriti Vihaan Trust and Neo Income Plus Fund III.
- Value
- ₹3.00 Cr
- Execution
- Ensuing month(s)
Amwill Health Care Management Change
Amwill Health Care Ltd re-appointed Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for a five-year term, effective January 27, 2027.
- Execution
- 5 years
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.